Traws Pharma, Inc.
About Traws Pharma, Inc.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing small synthetic molecules for respiratory viral diseases and cancer. It focuses on investigational therapies for influenza and COVID-19 designed to address treatment resistance, including Tivoxavir marboxil (endonuclease inhibitor) and Ratutrelvir (protease inhibitor). The company was formed in 2024 through a business combination of Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. It is headquartered in Newtown, Pennsylvania and maintains a website at www.trawspharma.com.
- 🔗 Traws Pharma, Inc Revenue, Funding & Valuation
- 🔗 Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
- 🔗 Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
- 🔗 Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company - BioSpace
- 🔗 Traws Pharma, Inc.
Investors
Key highlights
- Formed via 2024 merger of Onconova Therapeutics and Trawsfynydd Therapeutics.
- Raised $14 million private placement led by OrbiMed and Torrey Pines with expected $28 million post-close cash.
- Pipeline includes Tivoxavir marboxil for influenza and Ratutrelvir for COVID-19.
- Also advancing narazaciclib, a next-generation CDK4/6 inhibitor for endometrial cancer.
- Reports 1-10 employees and $20 million total funding to date.
Ask StreetZero about Traws Pharma, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account